Brinker Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Brinker Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$8.87M	Buy	14,216 +2,480	+21%	+$1.41M	0.28%	75
2020 Q1	$5.73M	Sell	11,736 -2,829	-19%	-$1.17M	0.23%	100
2019 Q4	$5.47M	Buy	14,565 +821	+6%	+$276K	0.17%	128
2019 Q3	$3.81M	Sell	13,744 -406	-3%	-$120K	0.13%	162
2019 Q2	$4.43M	Sell	14,150 -1,213	-8%	-$404K	0.16%	133
2019 Q1	$6.31M	Buy	15,363 +1,893	+14%	+$780K	0.24%	93
2018 Q4	$5.03M	Sell	13,470 -80	-0.6%	-$29.3K	0.22%	103
2018 Q3	$5.47M	Sell	13,550 -705	-5%	-$268K	0.2%	107
2018 Q2	$4.92M	Buy	14,255 +122	+0.9%	+$38.2K	0.19%	112
2018 Q1	$4.87M	Buy	14,133 +4,269	+43%	+$1.48M	0.19%	112
2017 Q4	$3.71M	Buy	9,864 +1,186	+14%	+$480K	0.14%	152
2017 Q3	$3.88M	Buy	+8,678	New	+$4.13M	0.16%	137
2017 Q2	–	Sell	-7,462	Closed	-$2.89M	–	842
2017 Q1	$2.89M	Buy	7,462 +2,505	+51%	+$929K	0.14%	159
2016 Q4	$1.82M	Buy	+4,957	New	+$1.89M	0.1%	198

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Brinker Capital's REGN Position: Q2 2020 in Review

Brinker Capital increased its Regeneron Pharmaceuticals (REGN) stake by 21% in Q2 2020, buying an estimated $1.41M and bringing the position to 14,216 shares worth $8.87M. The position accounts for 0.28% of the portfolio, ranked #75.

Brinker Capital first reported a position in REGN in Q4 2016 and has held it in 14 quarters since. 933 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

Brinker Capital held 14,216 shares of Regeneron Pharmaceuticals worth $8.87M as of Q2 2020.
Brinker Capital bought 2,480 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $1.41M.
Regeneron Pharmaceuticals made up 0.28% of Brinker Capital's portfolio in Q2 2020, its #75 holding.
Brinker Capital first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 14 quarters since.
933 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.